The world has been plunged into an unprecedented public health and economic crisis. In order to return to normality and begin to recover, the race is on to find an effective vaccine against Covid-19 and manufacture the millions of doses required to build immunity, a process that can typically take more than a decade.
Thankfully, the UK is exceptionally well placed – with established tools, technologies and expertise – to rise to this challenge, as Lucy Foley, Director of Biologics at CPI, explains. Over the past 15 years, the UK has been cementing its position as a global leader in biopharmaceutical research and next0generation manufacturing. This position is supported…
This content is for subscribers only. Subscribe now for free to read the full article.
Already a subscriber? Login
